According to the Zhitong Finance App, Beida Pharmaceutical (300558.SZ) released its 2026 semi-annual results forecast. The net profit for the first half of the year is expected to be 308 million yuan to 392 million yuan, an increase of 120%-180% over the previous year.

Currently, the company sells a total of nine drugs, forming a product matrix covering various fields such as lung cancer, kidney cancer, and breast cancer. The company comprehensively promotes independent research and development, marketing, strategic cooperation, and the collaborative development strategy of the “four carriages” of the innovation ecosystem, and continues to develop and introduce differentiated and iterative innovative drugs. Relying on differentiated competitive advantages, health insurance policy dividends, and a perfect and mature commercial network, the market sales scale continued to expand, and the main business revenue rose steadily in the first half of 2026. The company continues to improve management capabilities, continue to improve quality and efficiency, and overall operating efficiency continues to improve. Net profit attributable to shareholders of listed companies increased dramatically in the current period, and net profit after deducting non-recurring profit and loss maintained significant growth.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.